The FDA has approved a life-extending treatment for advanced pancreatic cancer — the first such therapy to attack a genetic cause of the highly lethal malignancy.

The therapy is a brand new targeted drug for the disease which experts have labelled as a substantial breakthrough following doubling of survival time in a trial.

Rasonque joins a short list of treatment options for one of the country’s deadliest types of cancer.